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Objectives. This study sought to evaluate the cost-effectiveness
of primary angioplasty for acute myocardial infarction under
varying assumptions about effectiveness, existing facilities and
staffing and volume of services.
Background. Primary angioplasty for acute myocardial infarc-
tion has reduced mortality in some studies, but its actual effec-
tiveness may vary, and most U.S. hospitals do not have cardiac
catheterization laboratories. Projections of cost-effectiveness in
various settings are needed for decisions about adoption.
Methods. We created a decision analytic model to compare
three policies: primary angioplasty, intravenous thrombolysis
and no intervention. Probabilities of health outcomes were taken
from randomized trials (base case efficacy assumptions) and
community-based studies (effectiveness assumptions). The base
case analysis assumed that a hospital with an existing laboratory
with night/weekend staffing coverage admitted 200 patients with a
myocardial infarction annually. In alternative scenarios, a new
laboratory was built, and its capacity for elective procedures was
either 1) needed or 2) redundant with existing laboratories.
Results. Under base case efficacy assumptions, primary angio-
plasty resulted in cost savings compared with thrombolysis and
had a cost of $12,000/quality-adjusted life-year (QALY) saved
compared with no intervention. In sensitivity analyses, when there
was an existing cardiac catheterization laboratory at a hospital
with >2200 patients with a myocardial infarction annually, pri-
mary angioplasty had a cost of <$30,000/QALY saved under a
wide range of assumptions. However, the cost/QALY saved in-
creased sharply under effectiveness assumptions when the hospi-
tal had <150 patients with a myocardial infarction annually or
when a redundant laboratory was built.
Conclusions. At hospitals with an existing cardiac catheteriza-
tion laboratory, primary angioplasty for acute myocardial infarc-
tion would be cost-effective relative to other medical interventions
under a wide range of assumptions. The procedure’s relative
cost-ineffectiveness at low volumes or redundant laboratories
supports regionalization of cardiac services in urban areas.
However, approaches to overcoming competitive barriers and
close monitoring of outcomes and costs will be needed.
(J Am Coll Cardiol 1997;30:1741–50)
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Recent randomized, controlled trials (1,2) have shown im-
proved outcomes after primary angioplasty compared with
intravenous thrombolysis for acute myocardial infarction. In
these research settings, primary angioplasty appeared no more
expensive than thrombolysis (3–5). However, the prospect of
providing primary angioplasty to general populations poses
several dilemmas.
If provided in the community, primary angioplasty may be
less beneficial than in research settings (6,7). Hospitals with
a lower volume of procedures have worse outcomes and
higher costs (8 –11). In addition, 80% of U.S. hospitals are
not equipped to provide primary angioplasty, and the costs
of the procedure would increase if new cardiac catheteriza-
tion laboratories needed to be built (12). Regionalization of
emergency services for chest pain might be one way of
directing patients to high volume hospitals, but any addi-
tional transit time needed could reduce the procedure’s
benefit (13).
Projections of cost-effectiveness under both efficacy and
effectiveness assumptions in a variety of settings are needed for
decisions about whether primary angioplasty should be
more widely adopted, and how services can be most effec-
tively organized. This study evaluated the cost-effectiveness
of primary angioplasty relative to thrombolysis and no
intervention for a hypothetical cohort of 10,000 patients
with acute myocardial infarction under a wide range of
assumptions about health outcomes, costs and hospital
characteristics.
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Methods
Model Structure
We developed a model to evaluate the health outcomes and
costs of primary angioplasty and intravenous thrombolytic
treatment of suspected acute myocardial infarction from the
societal perspective. The model (Fig. 1) was used to evaluate
three clinical policies for treating acute myocardial infarction:
primary angioplasty, thrombolysis and no intervention. No
intervention was defined as all patients receiving neither throm-
bolysis nor primary angioplasty but still admitted to the
hospital for standard care.
Patient subgroups. Patients were classified into four sub-
groups on the basis of clinical characteristics:
1. Cardiogenic shock—these patients were considered to al-
ways be eligible for primary angioplasty or thrombolysis.
2. Ineligible for intervention—other patients presenting .6 h
after the onset of symptoms, without $1 mm ST segment
elevation in two contiguous electrocardiographic leads, or
with complete left bundle branch block, were considered
ineligible for thrombolysis or primary angioplasty and
would have no intervention.
3. Bleeding risk factors—patients with specific risk factors for
bleeding, as defined by previous studies (14,15) would be
ineligible for thrombolysis but eligible for primary angio-
plasty.
4. Candidates for thrombolysis—the remaining patients were
considered eligible for either thrombolysis or primary an-
gioplasty.
Interventions. Primary angioplasty policy. Under the pri-
mary angioplasty policy, patients with cardiogenic shock, pa-
tients with bleeding risk factors and candidates for thrombol-
ysis all would undergo coronary arteriography. Those with
potentially treatable lesions would undergo attempted angio-
plasty without preceding intravenous or intracoronary throm-
bolytic treatment.
Thrombolysis policy. Under the thrombolysis policy, candi-
dates for thrombolysis would receive intravenous infusion of
either streptokinase or tissue-type plasminogen activator (t-
PA). The choice of intervention for the other patient sub-
groups would depend on whether the hospital had a cardiac
catheterization laboratory. At hospitals with an existing labo-
Figure 1. Decision tree illustrating possible clinical policies for a
hypothetical population of patients with an acute myocardial infarc-
tion. Squares 5 decision by the clinical policymaker; circles 5 chance
events not under the direct control. Under the No Intervention Policy,
all patients receive standard hospital treatment for acute myocardial
infarction, including heparin and aspirin. Under the Thrombolysis
Policy, those patients who are candidates for thrombolysis receive a
thrombolytic agent and standard care; those in cardiogenic shock
undergo either attempted angioplasty or receive thrombolysis, fol-
lowed by transport, if possible. Under the Primary Angioplasty Policy,
all patients undergo attempted angioplasty, unless they are ineligible
because of a nonqualifying electrocardiogram or symptom duration
.6 h. *For a hospital without an existing cardiac catheterization
laboratory: 1) under the Primary Angioplasty Policy, a new laboratory
would be built; 2) under the Thrombolysis Policy, no new laboratory
would be built.
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CMIS 5 Cost Management Information
System
QALY 5 quality-adjusted life-year
t-PA 5 tissue-type plasminogen activator
1742 LIEU ET AL. JACC Vol. 30, No. 7
PRIMARY ANGIOPLASTY COST-EFFECTIVENESS December 1997:1741–50
ratory, patients with cardiogenic shock or bleeding risk factors
were assumed to undergo primary angioplasty as the preferred
intervention when the admitting hospital had a cardiac cathe-
terization laboratory. At hospitals without an existing labora-
tory, patients with bleeding risk would receive no intervention,
and those with cardiogenic shock would receive thrombolysis.
When possible, patients with cardiogenic shock would be
transported to a neighboring hospital for primary angioplasty.
Because .50% of the U.S. population lives in metropolitan
areas, transport was assumed to be possible for 50% of patients
with cardiogenic shock (16).
Hospital characteristics. A base case hospital (“Fully Cov-
ered Lab” scenario) was defined as follows: It had an existing
cardiac catheterization laboratory that performed elective pro-
cedures during weekdays and had cardiovascular surgical
backup. Night call for two technical staff members was as-
sumed to be already covered. Primary angioplasty was assumed
to be offered 24 h/day, every day. We inferred from two
previous studies (17,18) that ;50% of all patients with a
myocardial infarction present to hospitals that treat at least 150
myocardial infarctions/year (17,18). Thus, the base case hospi-
tal was assumed to have 200 annual discharges for acute
myocardial infarction.
Data and Assumptions: Health Outcomes
Probabilities of health outcomes (Table 1) were derived
from a review of published reports (19), unpublished studies,
analyses of Kaiser Permanente data and an expert panel
conference. Seven cardiologists (see Acknowledgments) con-
vened in person to review evidence tables that summarized the
published reports about each assumption. To derive each final
base case estimate, a modified Delphi approach was used in
which each panelist submitted initial estimates, then reviewed
and adjusted results to reach as much consensus as possible.
The base case used efficacy assumptions about health out-
comes based on published randomized trials.
Table 1. Health Outcomes After Interventions for Acute Myocardial Infarction
Outcome
Base Case Estimate (effectiveness estimate)
if Treated With
Ref No. or
Other Source
Primary
Angioplasty Thrombolysis
No
Intervention
In-hospital mortality among patient subgroups
In cardiogenic shock 0.52 (0.71) 0.71 0.85 23–30
Ineligible for intervention NA NA 0.10 15, 54–57
With bleeding risk factors 0.12 (0.26) NA 0.26 31, 32
Thrombolysis candidates 0.04 (0.06) 0.06 0.08 1, 2, 36–38
Among thrombolysis candidates
Nonfatal disabling stroke 0.0015 0.005 0.002 1, 33, 37
Bleeding requiring transfusion 0.03 0.02 0.005 Expert panel*
1-yr survival rate 0.93 (0.92) 0.92 0.85 4, 14, 15, 35, 36, 38, 40, 58–63
1-yr reinfarction rate 0.10 (0.10) 0.10 0.05 38, 40, 59, 61, 64–66
5-yr survival rate 0.82 (0.82) 0.82 0.77 58, 61, 64, 67
Procedure rates 1, 4–6, 38
CABG during hospital stay 0.10 (0.12) 0.12 0.09
CABG during next year 0.09 (0.09) 0.09 0.10
Angioplasty during hospital stay 0.04 (0.05) 0.30 0.18
Angioplasty during next year 0.15 (0.15) 0.15 0.15
Average length of hospital stay for uncomplicated
myocardial infarction (days)†
3, 6
ICU 2.5 (2.5) 3 3.5
Telemetry unit 2 (2) 2.5 3
Medical ward 1.5 (1.5) 1.5 1.5
Total 6 (6) 7 8
Proportions in CCS classes at 1 yr among
candidates for thrombolysis
4
I 0.83 (0.68) 0.68 0.68
II 0.16 (0.25) 0.25 0.25
III or IV 0.01 (0.07) 0.07 0.07
*Seven cardiologists who convened for 1 day to review base case estimates and provide ranges for sensitivity analysis using a modified Delphi process (see
Acknowledgments). †Fifty percent of the days saved in the thrombolysis and primary angioplasty groups were assumed to be intensive care unit (ICU) days, and 50%
were assumed to be telemetry unit days; for patients with risk factors for bleeding or cardiogenic shock, primary angioplasty and thrombolysis were assumed to not save
any hospital days relative to no intervention. CCS 5 Canadian Cardiovascular Society; CABG 5 coronary artery bypass graft surgery; NA 5 not applicable (under the
primary angioplasty and thrombolysis policies, patients ineligible for intervention would have no intervention and would have an in-hospital mortality rate of 0.10; under
the thrombolysis policy, patients with bleeding risk would have no intervention and would have an in-hospital mortality rate of 0.26); Ref 5 reference.
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Patient subgroups. On the basis of published studies
(20,21) and a Kaiser Permanente analysis, we assumed that
among all patients with an acute myocardial infarction, 3%
presented in cardiogenic shock, 65% were ineligible for inter-
vention, and 6% had risk factors for bleeding. The remaining
26% were candidates for thrombolysis (eligible for either
thrombolysis or primary angioplasty).
The model took into account that the probability of myo-
cardial infarction among patients within 6 h of chest pain onset
and with ST segment was 95% (22). It was assumed that
patients without a myocardial infarction would incur treatment
costs but would not benefit from thrombolysis or primary
angioplasty.
Survival. In-hospital mortality rates (Table 1) were taken
from published studies and expert panel opinion (23–35).
Among candidates for thrombolysis, a published meta-analysis
and our expert panel suggested a 4% in-hospital mortality rate
after primary angioplasty and a 6% mortality rate after throm-
bolysis (1,2,36–39). For candidates for thrombolysis, 1-year
survival rates were based on randomized studies and a pub-
lished meta-analysis (4,36,40). It was assumed that survival
differences between primary angioplasty and thrombolysis
groups were markedly attenuated by 1 year and gone at 5 years.
For patients with cardiogenic shock (41) and bleeding risk,
long-term survival rates were assumed to be lower than those
of candidates for thrombolysis. Those who survived the hospi-
tal period were assumed to have the same life expectancy
whether they underwent primary angioplasty or received
thrombolysis. For the subgroup with bleeding risk factors,
there is no published evidence on long-term survival; they were
conservatively assigned a life expectancy equal to patients who
were ineligible for intervention. Life expectancy for each
subgroup was calculated by combining the appropriate survival
rates with estimates of long-term post-myocardial infarction
life expectancy from the Coronary Heart Disease Policy Model
(42).
Cardiac procedures and stroke. For candidates for throm-
bolysis who underwent primary angioplasty, rates of coronary
artery bypass graft surgery (CABG) and angioplasty during the
hospital period and the subsequent year were estimated from
published data (3,5). Rates of angioplasty and CABG during
the subsequent year were assumed to be equal between the
primary angioplasty and thrombolysis groups. The rate of
nonfatal disabling stroke after thrombolysis was based on the
largest available study (33).
Quality of life. The quality-adjusted life-year (QALY)
saved is a standard outcome measure in cost-effectiveness
analyses (43). It takes into account not only the mortality but
also the morbidity prevented by an intervention. Candidates
for thrombolysis were assumed to have better cardiac func-
tional status after primary angioplasty than after thrombolysis
on the basis of published information observed at 1 year after
the acute myocardial infarction (4) (Table 1). These health
states and their utilities were assumed to apply through the end
of life. Survivors with bleeding risk and with cardiogenic shock
were conservatively assumed to not derive any advantage in
cardiac quality of life after primary angioplasty, although they
derived some advantage from a lower rate of stroke.
Quality of life adjustments were made using utilities from
published patient preference studies; community weights for
these categories of health states are not available. For Cana-
dian Cardiovascular Society classes, utilities were 0.970 for
class I, 0.970 for class II and 0.875 for class III or IV (44). For
nonfatal disabling stroke, the utility was 0.10 (45).
Data and Assumptions: Costs
The analysis incorporated costs, including administrative
overhead, of the initial hospital period, major cardiac proce-
dures, reinfarction during the subsequent year and future
medical expenses through the end of life. We used direct
medical costs from the societal perspective in 1993 U.S.
dollars. Costs from other years were adjusted to 1993 dollars
using the medical component of the Consumer Price Index
(16).
Initial hospital period. Members of Northern California
Kaiser Permanente, a nonprofit health maintenance organiza-
tion, with an acute myocardial infarction in 1993 were identi-
fied using a standard algorithm for International Classification
of Diseases, 9th Revision (ICD-9) codes developed by the
California Office of Statewide Health Planning Development.
Patients with coronary artery bypass graft procedures were
identified using diagnosis-related group (DRG) codes. The
mean costs of hospital days in the intensive care unit, telemetry
unit and regular medical ward were analyzed for these patients
using Kaiser Permanente’s Cost Management Information
System (CMIS).
Using CMIS, length of stay was evaluated for patients
discharged in 1993 with a myocardial infarction (n 5 1,905,
mean 6.6 days), myocardial infarction with CABG (n 5 198,
mean 13 days) and CABG alone (n 5 372, mean 9.5 days). For
candidates for thrombolysis, projected lengths of hospital stay
were based on these data and on the expert panel’s consensus
(Table 1).
Cardiac procedures and reinfarction. The initial cost of
primary angioplasty was estimated using a previously described
model (11) that took into account four factors: 1) whether
cardiac catheterization laboratories already existed at a hospi-
tal; 2) whether the laboratory’s technical personnel were
already paid for night call; 3) how cardiovascular surgical
backup would be provided; 4) the hospital’s annual number of
discharges for myocardial infarction. Using the base case
hospital’s characteristics, the initial cost of a primary angio-
plasty procedure was $2,068, including physician costs.
The cost of an elective angioplasty procedure was calcu-
lated by adding the costs of cardiologist time, supplies, wages
for technical and clerical personnel and cardiac catheterization
laboratory maintenance and depreciation. Elective angioplasty
was assumed to require a hospital admission of 2 days.
Reinfarction in the subsequent year was assumed to require a
hospital admission of 7 days.
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Other costs. The base case used the cost of t-PA for
thrombolysis (Table 2). Treatment for bleeding complications
was assumed to include transfusion of 2 U of packed red cells
and two additional days in the cardiac care unit (46). The costs
of nonfatal disabling stroke were based on Kaiser Permanente
CMIS data and on estimates from the National Nursing Home
Survey (47,48). The estimated annual average cost of medical
care from the 1-year anniversary of the myocardial infarction
to the end of life (Table 2) was calculated on the basis of
published estimates from the National Medical Expenditure
Survey (49) and the Coronary Heart Disease Policy Model
(18).
Outcome Measures
An Excel spreadsheet was used to calculate health out-
comes, costs and cost-effectiveness ratios from the societal
perspective for a hypothetical cohort of 10,000 patients admit-
ted to the hospital with an acute myocardial infarction. This
cohort included 1,000 patients/year for 10 years. Results were
expressed in net present value averaged over the 10-year
period. In the base case, per current recommendations, future
costs and life-years to the end of each patient’s life were
discounted at 3%/year (43).
Incremental cost-effectiveness ratios were defined as the
additional cost per additional health benefit of primary angio-
plasty compared with thrombolysis and of thrombolysis com-
pared with no intervention. Primary angioplasty was defined as
having dominance when it was both more effective and cost
saving than thrombolysis and having extended dominance
when its incremental cost effectiveness ratio was lower than
that of thrombolysis. When dominance or extended dominance
existed, it was appropriate to calculate the cost-effectiveness of
primary angioplasty compared with no intervention (43).
Sensitivity Analyses
Uncertainty surrounds the assumptions in every decision
analysis. We varied four major factors both individually and
simultaneously, as follows: 1) the effectiveness of primary
angioplasty; 2) the hospital scenarios in which it might be
offered; 3) the volume of services; and 4) the time to treatment.
Sensitivity analyses were also conducted for individual assump-
tions, including in-hospital mortality, long-term survival, sub-
sequent cardiac quality of life, the cost of thrombolysis, the
cost of future medical care for survivors and the discount rate.
Effectiveness assumptions. The base case analysis used
efficacy assumptions about health outcomes from randomized,
controlled trials in optimal settings. We conducted an alterna-
tive analysis that used effectiveness assumptions from
community-based observational studies of primary angioplasty
and thrombolysis (6,7). In the effectiveness assumptions, pri-
mary angioplasty had no advantages over thrombolysis in
in-hospital mortality or future survival for any of the patient
subgroups. It was also assumed the primary angioplasty and
thrombolysis groups had identical rates of CABG during the
initial hospital period and rates of CABG and elective angio-
plasty during the next 12 months. The only advantages that
primary angioplasty retained over thrombolysis were a shorter
hospital stay and lower rates of nonfatal disabling stroke and
bleeding requiring transfusion. When the volume of annual
myocardial infarctions was varied, assumptions about health
outcomes were changed only when explicitly stated.
Hospital scenarios. The initial cost of primary angioplasty
was varied on the basis of 10 alternative sets of assumptions
about the admitting hospital, as previously described; three are
presented here (11). The “Add Night Call” scenario was
identical to the base case hospital (“Fully Covered Lab”
scenario), except that night call for two technical staff members
was a new expense.
The “Add Needed Lab” scenario assumed that the admit-
ting hospitals were in a geographic area where there had been
elective procedures going unperformed for want of a cardiac
catheterization laboratory. Thus, part of the new laboratories’
costs were apportioned to 100 elective angioplasty and 700
Table 2. Costs Used in Analysis of Interventions for Acute
Myocardial Infarction
Service Cost (U.S. 1993 $)
Ref No. or
Other Source
ICU day 1,845 CMIS*
Telemetry unit day 955 CMIS*
Medical ward day 700 CMIS*
CABG procedure† 9,160 KP‡
Elective angioplasty procedure† 2,068 KP‡
Primary angioplasty procedure§ 2,068 11
(varies)
Streptokinase 320 68
t-PA 2,750 68
Transport to neighboring hospital 500 KP**
Transfusion (2 U of packed RBCs) 225 KP**
Nonfatal disabling stroke
Initial rehabilitation 21,216 CMIS*
Outpatient physical therapy 1,248 CMIS*
Future nursing home care (400
days)
34,232 47, 48
Average annual medical costs from
1-yr anniversary of MI to end of
life
11,133 18, 49
*Estimate is from analysis of cases in Cost Management Information System
(CMIS) of Northern California Kaiser Permanente. †Professional time and
procedure costs (e.g., operating room, cardiac catheterization laboratory and
supplies) only; estimate includes overhead but does not include costs of hospital
stay; the cost of a coronary artery bypass graft surgery (CABG) procedure was
estimated on the basis of cardiovascular surgeons’ and anesthesiologists’ time
allocated for each procedure and the cost of cardiovascular operating room time,
which included technical personnel, room and equipment costs; after including
hospital costs, the total costs of an elective bypass surgery procedure would be
$23,000. ‡Estimate is based on analyses of Kaiser Permanente (KP) administra-
tive data. §Base case analysis estimate of $2,068 assumed an existing cardiac
catheterization laboratory and cardiovascular surgical backup; night call for
technical staff would be already covered, and the hospital would discharge 200
patients with myocardial infarction (MI)/year; costs under alternative scenarios
were $4,453 in the “Add Night Call” scenario, $5,140 in the “Add Needed Lab”
Scenario and $9,393 in the “Add Redundant Lab” scenario. RBCs 5 red blood
cells; t-PA 5 tissue-type plasminogen activator; other abbreviations as in Table 1.
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elective angiography procedures per year. In contrast, in
Northern California and many other urban areas, excess
capacity for elective angioplasty and angiography already
exists. For this reason, the “Add Redundant Lab” scenario
assumed that the economic cost of building and equipping the
new laboratories was attributable entirely to primary angio-
plasty. When a new laboratory was built, it was assumed that
cardiovascular surgical backup would be provided by transport
to a neighboring hospital.
Time to intervention. If primary angioplasty services were
regionalized, there might be delays in intervention due to
either increased travel time by emergency medical services or
time required for transfer if the patient initially presented to a
hospital without primary angioplasty. Data from the Global
Utilization of Streptokinase and Tissue Plasminogen Activator
for Occluded Coronary Arteries (GUSTO) (50) trial were used
to estimate the proportions of candidates for thrombolysis
ready for intervention at 0 to 2 h (20%), 2 to 4 h (50%) and 4
to 6 h (30%) after symptom onset. The absolute decrease in
benefit from a 1-h delay in reperfusion at 0 to 2 h (2%), 2 to 4 h
(0.5%) and 4 to 6 h (none) was nonlinear and was estimated
from a summary of recent thrombolysis trials (51). Combining
these data, we assumed that a 1-h delay in primary angioplasty
would result in an average 0.65% absolute increase in mortality
for candidates for thrombolysis. Only candidates for thrombol-
ysis who had undergone attempted angioplasty under the
primary angioplasty policy were assumed to have the 1-h delay;
those treated under the thrombolysis policy were assumed not
to have a delay.
Results
Health outcomes. For the hypothetical cohort of 10,000
patients with an acute myocardial infarction, under the base
case (efficacy) assumptions, primary angioplasty was predicted
to save 22% more lives and to reduce nonfatal disabling
strokes by one-third compared with thrombolysis (Table 3).
The improvement in survival was 741 undiscounted QALYs
(514 discounted QALYs) relative to thrombolysis.
Costs and cost-effectiveness. The primary angioplasty pol-
icy would save $7.2 million in short-term costs compared with
thrombolysis (Table 3). This was due to the primary angio-
plasty procedure’s slightly lower cost than that of t-PA and the
projected savings in hospital days. Even after the costs of
lifetime medical care for hospital survivors were included,
primary angioplasty would lead to cost savings of $1.9 million
relative to thrombolysis.
Primary angioplasty dominated thrombolysis because it had
both superior health outcomes and lower costs. In this situa-
tion, it was appropriate to express the cost/QALY saved by
primary angioplasty compared with no intervention, which was
$12,000.
Sensitivity analyses. Effectiveness assumptions and hospital
scenarios. For the base case hospital with an existing, fully
staffed laboratory, using effectiveness rather than efficacy as-
sumptions resulted in only a slight increase in the cost/QALY
saved by primary angioplasty, still $12,000. Likewise, primary
angioplasty continued to have a cost/QALY saved of ,$30,000
under alternative hospital scenarios, provided that efficacy
assumptions were used and the hospital’s annual volume of
myocardial infarctions was $200 (Fig. 2).
However, when effectiveness assumptions were combined
with alternative hospital scenarios, primary angioplasty ap-
peared much less cost-effective. Under effectiveness assump-
tions and at an annual volume of 200 myocardial infarctions,
the cost/QALY saved increased to $72,000 in the “Add
Needed Lab” scenario and to $330,000 in the “Add Redundant
Lab” scenario (Fig. 2).
Procedure volume. Under the “Add Night Call,” “Add
Needed Lab” and “Add Redundant Lab” scenarios, the cost/
QALY saved by primary angioplasty increased sharply as the
annual number of patients with an acute myocardial infarction
admitted to the hospital decreased (Fig. 2). When effectiveness
assumptions were used and the hospital admitted ,150 pa-
tients with a myocardial infarction/year, the cost/QALY saved
increased to .$100,000 in all hospital scenarios except the
base case hospital.
Time to intervention. Under base case efficacy assumptions,
increasing the time to intervention by 1 h reduced the undis-
counted QALYs saved by the primary angioplasty policy to
3,986 relative to no intervention (a 5% reduction) and 544
relative to thrombolysis (a 26% reduction). However, primary
angioplasty was still cost saving compared with thrombolysis
and had a cost/QALY saved of $12,000 compared with no
intervention. In contrast, under effectiveness assumptions,
increasing the time to intervention by 1 h resulted in higher
total mortality than thrombolysis, rendering this an ineffective
strategy no matter what the cost.
Other sensitivity analyses. For the base case hospital, the
“Add Night Call” scenario, and the “Add Needed Lab”
scenario, primary angioplasty always had a cost/QALY saved
of ,$20,000 when individual assumptions (e.g., in-hospital
mortality, long-term survival, subsequent cardiac quality of
life) were varied over plausible ranges. When the cost of
thrombolysis was changed to that of streptokinase ($320),
primary angioplasty’s cost/QALY was $7,000 compared with
thrombolysis, still less than that of thrombolysis compared with
no intervention. When future medical costs were not included,
the cost/QALY saved compared with no intervention ranged
from $400 for the base case hospital to $18,000 for the “Add
Redundant Lab” scenario. At a discount rate of 5% rather
than 3%, primary angioplasty still had projected cost savings
compared with thrombolysis and a cost of $12,000/QALY
saved compared with no intervention.
Discussion
Main findings. From a societal perspective, primary angio-
plasty for acute myocardial infarction would have reasonable
cost-effectiveness under a wide range of assumptions if pro-
vided by hospitals that already have fully supported cardiac
catheterization laboratories. Under base case assumptions, the
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procedure was projected to save costs compared with throm-
bolysis and to cost $12,000/QALY saved compared with no
intervention. The latter ratio is lower than those of many other
accepted medical interventions. These findings are in accord
with empirical studies (3–5) suggesting that the cost-
effectiveness of primary angioplasty under ideal conditions is
better than or equal to that of thrombolysis.
However, these results also underscore the potential cost-
ineffectiveness of primary angioplasty if provided in settings
where health outcomes are similar to those in observational
community-based studies and where the procedure’s costs are
higher or volumes are lower. Under effectiveness assumptions
and at low volumes, the cost/QALY saved under most hospital
scenarios rapidly increased beyond $100,000, out of the range
of most accepted medical interventions.
Policy implications. Our findings suggest that regionaliza-
tion of cardiac services would be desirable from a societal
perspective. Providing primary angioplasty cost-effectively will
depend on using existing cardiac catheterization laboratories
and maximizing hospitals’ volumes of procedures. Without
regionalization, the procedure might be offered by hospitals
with a lower volume or less experienced operators, which tends
to lead to worse angioplasty outcomes (6,8,10).
The present study was conducted to inform health policy
decisions rather than to direct individual bedside decisions.
The results suggest that primary angioplasty would have rea-
sonable cost-effectiveness if optimal costs and outcomes could
be achieved, even if the average time to intervention increased
by 1 h. In urban areas, where ;80% of the U.S. population
resides, regionalization might be achieved by having emer-
gency medical services triage symptomatic patients to high
volume hospitals with primary angioplasty capability.
In reality, the conflicting perspectives of the various stake-
holders in health care may pose a barrier to optimal use of
Table 3. Projected Outcomes of Primary Angioplasty and Thrombolysis Policies for a Hypothetical
Cohort of 10,000 Patients With Acute Myocardial Infarction
Clinical Policy
Primary
Angioplasty Thrombolysis No Intervention
Health outcomes
Deaths 982 1,034 1,269
Survivors 9,018 8,966 8,731
Nonfatal disabling strokes 16 25 17
Relative to no intervention
Lives saved 287 235 NA
Life-years saved (undiscounted) 4,310 3,626 NA
QALYs saved (undiscounted) 4,183 3,442 NA
Relative to thrombolysis
Lives saved 52 NA NA
Life-years saved (undiscounted) 684 NA NA
QALYs saved (undiscounted) 741 NA NA
Costs [U.S. $ in thousands (% of total costs)]*
Initial intervention 6,500 (1) 8,100 (1) NA
Initial hospital stay 102,000 (14) 107,000 (15) 108,000 (16)
Reinfarction and procedures in subsequent 12 mo 30,000 (4) 30,000 (4) 29,000 (4)
Subtotal for 12 mo 138,000 (19) 145,000 (20) 137,000 (20)
Future health costs of survivors 585,000 (81) 581,000 (80) 553,000 (80)
Total 724,000 (100) 726,000 (100) 690,000 (100)
Incremental 12-mo cost (savings)† (7,200) 8,300 NA
Incremental total cost† (1,900) 36,000 NA
Cost-effectiveness ratios‡
Vs. thrombolysis
$/life saved Savings NA NA
$/life-year saved Savings NA NA
$/QALY saved Savings NA NA
Vs. no intervention§
$/life saved 120,000 150,000 NA
$/life-year saved 11,000 14,000 NA
$/QALY saved 12,000 15,000 NA
*U.S. 1993 dollars, discounted at 3%/year over 10 years; numbers are rounded to two or three significant digits and
thus do not always add to total. †Incremental costs are primary angioplasty versus thrombolysis and thrombolysis versus
no intervention. ‡Costs and benefits discounted at 3%/year. §Primary angioplasty is considered economically preferable
to thrombolysis by the principle of extended dominance, because the cost/quality-adjusted life-year (QALY) saved of
primary angioplasty relative to thrombolysis is lower than that of thrombolysis relative to no intervention; thus, the
cost/QALY saved of primary angioplasty relative to no intervention is given. NA 5 not applicable.
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primary angioplasty. In the United States, decisions about
health services are usually made at the level of the individual
hospital or health plan, and this poses competitive barriers to
regionalization. An individual hospital in a competitive market
may seek to maximize revenue and market share by providing
profitable services such as invasive cardiac procedures, even if
they duplicate those of neighboring hospitals and preclude
cooperation.
A large health maintenance organization may need to
contract with outside hospitals to provide primary angioplasty
services and would most likely face higher charges for primary
angioplasty than the optimal cost of ;$2,000 in our base case,
possibly closer to the $5,000 cost in our “Add Needed Lab”
scenario. In addition, most patients with chest pain do not
actually have an acute myocardial infarction. If emergency
medical services triaged all patients with chest pain to regional
centers without attempting to select those with an acute
myocardial infarction, costs to a third-party payer could in-
crease even more. Thus, if regional triaging is considered, close
monitoring of actual costs and outcomes will be warranted to
avoid providing primary angioplasty in a cost-ineffective man-
ner.
Limitations of the study. In this study, primary angioplasty
did not result in long-term cost savings compared with no
intervention, in part because increased survivorship led to
higher costs of future lifetime medical care. Including these
costs presents the most accurate picture of a policy’s effects
(52). When future medical costs were not included, the costs/
QALY saved by primary angioplasty appeared to be 50% to
90% lower. Estimates from other studies, such as the $33,000/
life-year saved by t-PA versus streptokinase, usually have not
included such costs (53).
Although we did not include work-loss costs, this would not
have changed our conclusions because patients who undergo
primary angioplasty have at least equal and possibly better
cardiac functional status than those who receive thrombolysis
(4). This analysis used the wholesale price of t-PA, which may
be higher than the true cost to society of manufacturing the
medication. However, the results did not change when the
lower price of streptokinase was used. New thrombolytic
agents or other technologies under development may have
lower stroke rates or superior effectiveness than t-PA, but this
analysis showed that primary angioplasty would be cost-
effective relative to thrombolysis even without any advantage
in stroke rates.
Conclusions. Primary angioplasty for patients with an
acute myocardial infarction is likely to be cost-effective at
hospitals that already have fully supported cardiac catheteriza-
tion laboratories operating at high volumes. The procedure’s
relative cost-ineffectiveness at low volumes supports regional-
ization of cardiac services in urban areas. However, if primary
angioplasty services are to be effectively regionalized in the
United States, creative approaches to overcoming competitive
barriers and close monitoring of outcomes and costs will be
needed.
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Figure 2. Cost/QALY saved by using a policy
of primary angioplasty, depending on proce-
dure volume (based on the number of acute
myocardial infarctions/year at the admitting
hospital). Solid lines 5 cost/QALY saved
under the three alternative hospital scenarios
given base case (efficacy) assumptions about
health outcomes; dashed lines 5 cost/QALY
saved under the three alternative hospital
scenarios, given effectiveness assumptions es-
timated from community-based observational
trials; solid symbols 5 analyses where pri-
mary angioplasty is compared with thrombol-
ysis; open symbols 5 analyses where primary
angioplasty had dominance or extended dom-
inance over thrombolysis and is thus com-
pared with no intervention. When volume is
varied, assumptions about health outcomes
are not changed, except as depicted using the
dashed lines for effectiveness assumptions.
The cost/QALY saved by primary angioplasty
under the base case hospital (“Fully Covered
Lab” scenario) was not depicted and re-
mained at $12,000 compared with no inter-
vention under both efficacy and effectiveness
assumptions regardless of volume. Using low
volumes and effectiveness assumptions about
health outcomes, the cost/QALY saved was
.$100,000 under most hospital scenarios.
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